Clinico-epidemiological profile of thalassemia patients in a tertiary care center
Abstract
Introduction: Thalassemias are inherited blood disorders characterized by abnormal hemoglobin production. There are two main types, alpha thalassemia, and beta-thalassemia. Beta Thalassemia Major (also called Cooley's Anemia) is a serious illness. Symptoms appear in the first two years of life and include paleness of the skin, poor appetite, irritability, and failure to grow. There is absent or decreased production of normal hemoglobin, resulting in microcytic anemia of varying degrees. The thalassemias have a distribution concomitant with areas where P. falciparum malaria is common. The alpha thalassemias are concentrated in Southeast Asia, Malaysia, and southern China. The beta thalassemias are seen primarily in the areas surrounding the Mediterranean Sea, Africa, and Southeast Asia. Proper treatment includes routine blood transfusions and other therapies which can lead to iron overload and contraction of infections such as HIV, HCV, and HBV shortening the life span of patients. On the other hand, inadequate transfusions may lead to severe anemia and debility.
Material and Methods: This retrospective record-based cross-sectional study was conducted in S.N. Medical College, Agra.
Results: In our tertiary center, we have 103 registered patients of thalassemia, in which 44 are females and 59 are males. Out of the 103 thalassemia cases, 95 (92.2%) belonged to beta-thalassemia major, 4(3.8%) of beta-thalassemia intermediate, and 1 (0.9%) of beta-thalassemia minor category. Fever was the most common presenting symptom. Pallor and hepatomegaly were the most common signs among cases.
Conclusion: Hemoglobinopathies are the commonest hereditary disorders in India and pose a major health problem. The data on the prevalence of β-thalassemias and other hemoglobinopathies in different caste/ethnic groups of India is scarce.
Downloads
References
2. Shekhar HU, Kabir Y, Hossain MM, Mesbah-Uddin M, Khatun-EJannat K, Hossain MS, et al. Blood transfusion mediated viral infections in thalassemic children in Bangladesh. J Med Sci. 2007;7(1):131-135. doi: 10.3923/jms.2007.131.135
3. Lokeshwar MR. Late Hony. Surg. Cmde. Dr. Shantilal C. Sheth oration presentation during PEDICON 2006, Delhi, January 6th, 2006. Progress in the management of thalassemia. Indian Pediatr. 2006;43 (6): 503-506.
4. Bashyam MD1, Bashyam L, Savithri GR, Gopikrishna M, Sangal V, Devi AR. Molecular genetic analyses of beta-thalassemia in South India reveals rare mutations in the beta-globin gene. J Hum Genet. 2004; 49(8):408-413. Epub 2004 Jul 24. doi: 10.1007/s10038-004-0169-9
5. Balgir RS. Spectrum of hemoglobinopathies in the state of Orissa, India: a ten years cohort study. J Assoc Physicians India. 2005;53:1021-1026.
6. Manglani M1, Lokeshwar MR, Vani VG, Bhatia N, Mhaskar V. 'NESTROFT'--an effective screening test for beta thalassemia trait. Indian Pediatr. 1997;34(8): 702-707.
7. Varawalla NY, Old JM, Sarkar R, Venkatesan R, Weatherall DJ. The spectrum of beta-thalassaemia mutations on the Indian subcontinent: the basis for prenatal diagnosis. Br J Haematol. 1991;78(2):242-247. doi: 10.1111/j.1365-2141.1991.tb04423.x
8. Thavorncharoensap M1, Torcharus K, Nuchprayoon I, Riewpaiboon A, Indaratna K, Ubol BO. Factors affecting health-related quality of life in Thai children with thalassemia. BMC Blood Disord. 2010;10:1. doi: 10.1186/1471-2326-10-1.
9. Angastiniotis M, Modell B, Englezos P, Boulyjenkov V. Prevention and control of haemoglobinopathies. Bull World Health Organ. 1995;73(3):375-386.
10. Angastiniotis M, Kyriakidou S, Hadjiminas MG. How thalassemia was controlled in Cyprus. World Health Forum. 1986;7(3):291-297.
11. Taneja R, Malik P, Sharma M, Agarwal MC. Multiple transfused thalassemia major: ocular manifestations in a hospital-based population. Indian J Ophthalmol. 2010; 58(2):125-130. doi: 10.4103/0301-4738. 60083.
12. Shanthi G, Balasubramanyam D, Srinivasan R. Clinical and Demographical Studies of Beta ()–Thalassemia in Tamil Nadu. Res J Pharm Biol Chem Sci. 2013;4 (3):952-956.
13. Preethi BP, Monika K, Maitreyee DS, Rashmi K. A hospital-based study of Hereditary Hemolytic Anaemias in Davanagere district of Karnataka, India. Bang J Med Sci. 2010;9(3):154-160.
14. Kaddah N, Salama K, Kaddah AM, Attia R. Epidemiological study among thalassemia intermedia pediatric patients. Med J Cairo Univ. 2010;78(2).
15. Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V, editors. Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT) Nicosia (CY): Thalassaemia International Federation; 2014.
16. Chattopadhyay K, Biswas R, Bhattacherjee S, Bandyopadhyay R. An epidemiological study on the clinic-hematological profile of patients with congenital hemolytic anemia in a tertiary care hospital of Kolkata. Indian J Prev Soc Med 2012;43:372-377.
17. Hashemi AS, Ghilian R, Golestan M, Akhavan Ghalibaf M, Zare Z, Dehghani MA. The study of growth in thalassemic patients and its correlation with serum ferritin level. Iranian J Pediatr Hematol Oncol. 2011; 1(4):147-151.
18. Samarakoon PS, Wijesuriya AP. A clinical audit of thalassaemia management at the Lady Ridgeway Hospital for Children, Colombo. Sri Lanka J Child Health.2011;40(2):48-53.doi: 10.4038/sljch.v40i2. 3090
19. Talsania S, Talsania N, Nayak H. A cross sectional study of thalassemia in Ahmedabad city, Gujarat (Hospital based). Healthline. 2011;2(1):48-51.
20. Mallik S, Chatterjee C, Mandal PK, Sardar JC, Ghosh P, Manna N. Expenditure to treat thalassaemia: an experience at a tertiary care hospital in India. Iran J Public Health. 2010;39(1):78-84. Epub 2010 Mar 31.
21. Cazzola M, Borgna-Pignatti C, Locatelli F, Ponchio L, Beguin Y, De Stefano P. A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis. Transfus. 1997;37(2):135-140. doi: 10. 1046 /j. 1537-2995.1997.37297203514.x
Copyright (c) 2019 Author (s). Published by Siddharth Health Research and Social Welfare Society
This work is licensed under a Creative Commons Attribution 4.0 International License.